Edgewise Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $25520.0 on May 02 ’25. In the deal valued at $16.45 per share,1,551 shares were sold. As a result of this transaction, Russell Alan J now holds 18,521 shares worth roughly $0.27 million.
Then, MOORE JOHN R sold 1,930 shares, generating $31,757 in total proceeds. Upon selling the shares at $16.45, the General Counsel now owns 6,531 shares.
Before that, KOCH KEVIN sold 4,276 shares. Edgewise Therapeutics Inc shares valued at $70,358 were divested by the President and CEO at a price of $16.45 per share. As a result of the transaction, KOCH KEVIN now holds 20,619 shares, worth roughly $0.31 million.
Guggenheim initiated its Edgewise Therapeutics Inc [EWTX] rating to a Buy in a research note published on April 30, 2025; the price target was $41. A number of analysts have revised their coverage, including Scotiabank’s analysts, who decreased its forecast for the stock in early April from “a Sector outperform” to “a Sector perform”. Scotiabank began covering EWTX with “Sector outperform” recommendation on March 07, 2025. Stifel started covering the stock on January 22, 2025. It rated EWTX as “a Hold”.
Price Performance Review of EWTX
On Monday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock jump 1.65% to $14.82. Over the last five days, the stock has lost -10.40%. Edgewise Therapeutics Inc shares have fallen nearly -44.49% since the year began. Nevertheless, the stocks have fallen -29.06% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $10.60 was recorded on 04/07/25. SMA at 50 days reached $18.80, while 200 days put it at $24.70.
Levels Of Support And Resistance For EWTX Stock
The 24-hour chart illustrates a support level at 14.39, which if violated will result in even more drops to 13.97. On the upside, there is a resistance level at 15.53. A further resistance level may holdings at 16.25. The Relative Strength Index (RSI) on the 14-day chart is 43.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.71, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.26%. Stochastics %K at 32.22% indicates the stock is a holding.
The most recent change occurred on November 22, 2024 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $45 price target.
